Trial Profile

A Phase 1 Study of REGN6569, an Anti-GITR mAb, With Cemiplimab in Patients With Advanced Solid Tumor Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; REGN 6569 (Primary)
Indications Carcinoma; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

24 Feb 2025 Status changed from active, no longer recruiting to discontinued. (Sponsor decision)
19 Nov 2024 Planned End Date changed from 22 Jun 2026 to 16 Sep 2025.
19 Nov 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com